KR20120016861A - Pharmaceutical composition comprising the extract paeonia lactiflora, fraction thereof or compound isolated therefrom as an active ingredient - Google Patents

Abstract

PURPOSE: A pharmaceutical composition containing Paeonia lactiflora seed extract, fraction thereof, or compound isolated from the same is provided to suppress BACE-1 activity and to treat and prevent neurodegenerative diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating neurodegenerative diseases contains Paeonia lactiflora seed extract as an active ingredient. The neurodegenerative diseases include Alzheimer's dieses, Parkinsons's disease, progressive supranuclear palsy. The extract is prepared using water, alcohol of C1-C4, or mixture solvent thereof. The pharmaceutical composition contains Paeonia lactiflora seed fraction as an active ingredient. The pharmaceutical composition also contains compounds as an active ingredient. The method for preparing the compounds comprises: a step of adding water, C1-C3 alcohol, or mixture thereof to the Paeonia lactiflora seeds to prepare Paeonia lactiflora seed extract; a step of fractioning the extract with water, dichloromethane, and ethyl acetate to prepare a fraction; a step of performing silicagel column chromatography of the fraction.

Description

Pharmaceutical composition comprising the extract paeonia lactiflora, fraction particular or compound isolated there from as an active ingredient

The present invention relates to a pharmaceutical composition for preventing or treating degenerative brain disease, or health food, comprising a peony seed extract, a fraction thereof, or a compound separated therefrom as an active ingredient.

The present invention is an organic solvent extract of Peony seed, which inhibits the activity of the enzyme BACE-1 (beta-secretase), which promotes the production of beta-amyloid, which is well known as a causative agent of senile dementia such as Alzheimer's disease, and is isolated from it. Active substance trans-resveratrol, cis- epson-viniferin, 7a, 8a-cis- epson-viniferin, 7a, 8a-cis-ε-viniferin, BACE-1 containing vitisinol C, vitisinol F, gnetin H, suffruticosol A and suffruticosol B as active ingredients It relates to an inhibitor.

Dementia is defined as the gradual deterioration of memory and cognitive abilities that impair everyday life, and can be divided into vascular dementia and Alzheimer's dementia. Vascular dementia mainly corresponds to a case in which cerebral infarction or stroke occurs due to a blood clot formed in a blood vessel, and is known to cause symptoms such as memory loss due to damage to brain cells around the onset. On the other hand, Alzheimer's disease (AD), which accounts for far more than vascular dementia, is a progressive, progressive brain disease that initially causes memory loss, personality changes, and decreased thinking. Dies of pneumonia within a year; It is estimated that 3.5-10% of senior citizens over 65 years of age suffer from the disease, with an estimated 4 million patients in the United States alone. The social cost of treating the disease alone is a major illness for seniors who spend $ 100 billion annually in the United States alone. Alzheimer ' s in the brain tissue with the characteristic lesions of dementia beta- like the amyloid plaques containing amyloid (amyloid plaques), nerve fiber enriched material (neurofibrillary tangles) is formed causes an inflammatory response in immune cells destroy the Ca ^{2 +} channel In addition, by reducing the amount of acetylcholine, a neurotransmitter, memory and cognitive decline have been reported, but the exact etiology or treatment is still unknown. In addition, recent epidemiologic studies have reported that risk factors for cerebrovascular diseases such as hypertension, diabetes, hyperlipidemia and heart disease increase the incidence of Alzheimer's disease as well as vascular dementia.

 The modern medical view of cognitive decline caused by Alzheimer's dementia (AD) considers the widespread degeneration and loss of brain cholinergic neurons as the main cause of cognitive decline and is not compromised as a means to overcome this. Research is focused on developing drugs that can partially restore damaged cognitive function by increasing the activity of the remaining cholinergic nervous system. All four drugs (tacrine, rivastigmine, donepezil, and galantamine), currently recognized by the US Food and Drug Administration (FDA) as a treatment for Alzheimer's dementia, aim to enhance cognitive function by inhibiting the activity of acetylcholinease. Also known as acetylcholinesterase inhibitors.

Indeed, acetylcholinesterase inhibitors are the only drugs that have been approved to treat Alzheimer's dementia, but these drugs have only temporary relief in some patients with Alzheimer's dementia (40-50%). There is a drawback that it cannot last. In addition, due to the nature of the disease requires long-term administration, the acetylcholinesterase inhibitors that have been developed so far have been accompanied by various side effects, including hepatotoxicity has also been revealed as a problem. The main reason why the development of a cure for Alzheimer's dementia has been difficult is that the cause of Alzheimer's dementia is not known. However, according to recent genetic, cellular, and molecular biological advances, the amyloid hypothesis has been proposed as a hypothesis for the pathogenesis of Alzheimer's dementia. In other words, beta-amyloid is released from the amyloid precursor protein (APP) and freed beta-amyloid aggregates with each other to produce insoluble amyloid plaques. As a result, the production of neurofibrillary tangles is secondary. As it has been found that the accumulation of beta-amyloid in the brain and its neurotoxicity are a very important cause of Alzheimer's dementia, it is possible to inhibit the production, coagulation or toxicity of beta-amyloid like BACE-1 inhibitors. Investigations of substances with relatively low side effects have been intensively studied worldwide.

Beta-amyloid is a fragment of amyloid precursor protein produced by the action of proteases called gamma-secretase and beta-secretase by APP (beta-amyloid precursor protein), which is a precursor of amyloid protein. The enzyme beta-secretase, which plays a major role in the production of beta-amyloid, is generally called BACE and two types of BACE-1 and BACE-2 are known. Among them, BACE-1 has most of the activity of beta-secretase (about 90%) and is known to play a much more important role than BACE-2 in the production of beta-amyloid. Thus, substances that selectively inhibit the activity of BACE-1 is sufficiently recognized the value that can be used as a therapeutic agent for Alzheimer's dementia by blocking the production process of beta-amyloid, which is the cause of Alzheimer's dementia.

Meanwhile, Peony ( Paeonia lactiflora ) is a perennial herb of the genus Peony, belonging to the peony family. Peony flowers are beautiful and are grown for ornamental purposes. Root is a herbal medicine used in Korean medicine (Baekak, Jeokpak) and used as anemia, analgesic, blood pressure and antipyretic. However, there are few studies related to BACE-1 inhibitory activity in the extracts of the peony plant.

Thus, the present inventors completed the present invention by revealing that the extract of Peony seed and fractions thereof exhibit BACE-1 inhibitory effect.

An object of the present invention is to provide a pharmaceutical composition for preventing or treating degenerative brain disease, which contains a peony seed extract, a fraction thereof or a compound separated therefrom as an active ingredient.

It is another object of the present invention to provide a health food composition for preventing or improving degenerative brain disease, which contains a peony seed extract, a fraction thereof or a compound separated therefrom as an active ingredient.

Another object of the present invention is to provide a novel compound isolated from the peony seed extract.

Another object of the present invention is to provide a method for preparing the novel compound.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of degenerative brain disease, containing as an active ingredient extracts, fractions thereof or compounds isolated from the peony seed.

The present invention also provides a health food for preventing or improving degenerative brain disease, which contains an extract of a peony seed, a fraction thereof or a compound separated therefrom as an active ingredient.

Furthermore, the present invention provides a novel compound isolated from the peony seed extract represented by the following formula (1) and (2):

[Formula 1]

[Formula 2]

In addition, the present invention comprises the steps of adding a peony seed water, C ₁ ~ C ₄ alcohol or a mixture thereof to obtain a peony seed extract (step 1);

Fractionating the extract obtained in step 1 with water, dichloromethane and ethyl acetate to obtain a fraction (step 2);

The ethyl acetate fraction obtained in step 2 is subjected to silica gel column chromatography to provide a method for preparing the new compound, which comprises the step of separating and purifying the new compound (step 3).

The extract of the peony seed, fractions thereof or compounds isolated therefrom according to the present invention have a BACE-1 inhibitory effect, and thus are useful for the prevention or treatment of degenerative brain diseases such as Alzheimer's dementia, Parkinson's disease and advanced nuclear palsy. Can be.

1 is a schematic diagram of the extract and fraction of peony seed according to an embodiment of the present invention.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing or treating degenerative brain disease, which contains an extract of Paeonia lactiflora seed as an active ingredient.

In the composition according to the present invention, peony seed can be used without limitation, such as cultivated, harvested or commercially available.

In the composition according to the present invention, the extraction solvent for extracting the peony seed is preferably used methanol, methanol aqueous solution, ethanol, ethanol aqueous solution, butanol or a mixed solvent thereof, more preferably 80 to 100% ethanol, but It is not limited.

The amount of the extraction solvent is preferably 2 to 200 times the weight of the peony seed, more preferably 10 to 30 times, but is not limited thereto.

The extract of the peony seed extract is a method using an extraction device such as hot water extraction, dipping extraction, supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction, reflux cooling extraction and ultrasonic extraction or XAD and HP-20 Conventional extraction methods in the art may be used, such as a method using an adsorption resin, and the like, but is preferably heated and extracted at reflux or at room temperature, but is not limited thereto. When the extraction temperature is preferably 10 to 30 ℃, the extraction time is preferably 1 day to 20 days, more preferably 5 to 10 days, but is not limited thereto.

The present invention also provides a pharmaceutical composition for preventing or treating degenerative brain disease, which contains a fraction of peony seed as an active ingredient.

Fractions according to the invention

Adding peony seed to water, C ₁ to C ₄ alcohol or a mixture thereof to obtain a peony seed extract (step 1); And

The extract obtained in step 1 may be prepared by a method comprising the step (step 2) of obtaining a fraction by sequentially fractionating with water, dichloromethane and ethyl acetate.

Hereinafter, the manufacturing method according to the present invention will be described in more detail step by step with reference to FIG. 1.

First, step 1 according to the present invention is a step of obtaining peony seed extract as an extraction solvent.

The peony seed extract may be prepared by the method described above.

Next, step 2 is a step of obtaining a fraction by fractionating the extract obtained in step 1 with water, dichloromethane and ethyl acetate.

Specifically, the fraction was suspended in water, the peony seed extract obtained in step 1, separated into water and organic layers by adding dichloromethane, the organic layer was concentrated under reduced pressure and dried to obtain a dichloromethane fraction, Ethyl acetate is added to the water layer to separate the water layer and the organic layer, and the organic layer is preferably concentrated under reduced pressure and dried to obtain an ethyl acetate fraction.

At this time, the vacuum concentration is preferably a vacuum rotary evaporator, but is not limited thereto. In addition, drying is preferably carried out under reduced pressure drying, vacuum drying, boiling drying, spray drying, room temperature drying or freeze drying, more preferably freeze drying, but not always limited thereto.

Furthermore, the present invention provides a pharmaceutical composition for preventing or treating degenerative brain disease, which contains at least one compound selected from the group consisting of the compounds of Formulas 1 to 8 as an active ingredient.

Compounds of Chemical Formulas 1 to 2 may be prepared by a method of producing the fraction obtained in Step 2 by performing silica gel column chromatography to separate and purify the compound.

Specifically, the silica gel column chromatography is preferably performed one to several times of reverse phase or silica gel column chromatography. As the mobile phase, dichloromethane: methanol (40: 1-1: 1) or methanol: water (1: 1-5-1: 1) can be used. At this time, the solvent used is eluted by a concentration gradient elution method which is sequentially raised from nonpolar to polar or from polar to nonpolar, and the desired active fraction is obtained by measuring the BACE-1 inhibitory effect of the collected isolates.

The present invention also provides a novel compound isolated from the peony seed extract represented by the formula (1) or (2).

[Formula 1]

[Formula 2]

The novel compound isolated from the peony seed extract may be prepared by the method described above.

The peony seed extract, fractions or compounds isolated therefrom according to the present invention exhibit an inhibitory activity value (IC ₅₀ ) of 0.34 to 11.90 μg / ml for BACE-1 (see Table 5) to effectively inhibit BACE-1 activity. Therefore, it can be usefully used for the prevention or treatment of degenerative brain diseases such as Alzheimer's dementia derived from BACE-1.

The peony seed extract, fractions thereof, or compound separated therefrom of the present invention preferably comprises 0.1 to 50% by weight of the peony seed extract, fractions thereof, or compound separated therefrom, based on the total weight of the composition, but is not limited thereto. Do not.

The composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of a medicament.

The compositions according to the invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. have. Carriers, excipients and diluents that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient in the composition of the present invention, for example, starch, calcium carbonate, sucrose (sucrose), lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the patient's condition, weight, age, sex, The range varies depending on the diet, the rate of excretion, the severity of the disease, the form of the drug, the time of administration, the method of administration, the route of administration and the duration of administration. The daily dose is 0.0001 mg / kg to 500 mg / kg, preferably 0.001 mg / kg to 100 mg / kg, when the extract or fraction according to the present invention is lyophilized, once daily if necessary. To several doses.

The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.

The present invention also provides a health food for preventing or improving degenerative brain disease, which contains a peony seed extract, a fraction thereof or a compound separated therefrom as an active ingredient.

Peony seed extract, fractions or compounds isolated therefrom of the present invention inhibits the production of beta-amyloid, which is the cause of Alzheimer's type senile dementia, which has a BACE-1 inhibitory effect, preventing or improving degenerative brain diseases such as senile dementia. It can be used as health food.

There is no particular limitation on the kind of food. Examples of foods to which the above-mentioned substances may be added include dairy products including drinks, meat, sausages, breads, biscuits, rice cakes, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, Beverages, alcoholic beverages, vitamin complexes, and the like, and include all healthy foods in the conventional sense.

Peony seed extract, fractions thereof, or compounds separated therefrom of the present invention may be added to foods as is or used with other foods or food ingredients, and may be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose (for prevention or improvement). In general, the amount of the extract in the dietary supplement may be added to 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term intake for health and hygiene or health control purposes, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.

The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.

In addition to the above, the peony seed extract of the present invention, its fractions or compounds separated therefrom are various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors such as flavoring agents, colorants and neutralizing agents (cheese, chocolate, etc.) ), Pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition, the rhubarb extract of the present invention, fractions thereof may contain natural fruit juice and pulp for the preparation of fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0.1 to about 20 parts by weight per 100 parts by weight of the peony seed extract, fractions thereof or compounds isolated therefrom.

Hereinafter, the present invention will be described in detail by Examples and Experimental Examples.

However, the following examples are merely to illustrate the present invention, but the content of the present invention is not limited by the following examples.

< Example  1> Preparation of Peony Seed Extract

2 kg of dried peony seeds were cooled to 20 l of ethanol at room temperature for 1 week, filtered and the filtrate was concentrated under reduced pressure to obtain 214 g of ethanol extract.

< Example  2> Peony Seed Fraction  Produce

The ethanol extract of Example 1 was suspended in 10 L of distilled water, and then an equal amount of dichloromethane was added to separate the water and organic layers to obtain 21.9 g of a dichloromethane fraction. The water layer was partitioned with 10 L of ethyl acetate, and the obtained fraction was concentrated under reduced pressure to give 128.6 g of ethyl acetate fraction, and the remaining water layer was freeze-dried.

< Experimental Example  1> Peony Seed Extract BACE -1 inhibitory effect measurement

BACE-1 inhibitory effect was measured using a BACE-1 FRET Assay Kit (PanVera®), detailed test methods are as follows. First, 10 μl of ethanol extract was added to 10 μl of BACE-1 substrate solution (final concentration 250 nM), 10 μl of BACE-1 enzyme (final concentration 0.3 unit / mL) solution was added, and then incubated at room temperature for 60 minutes. . Immediately after completion of the incubation, 10 μl of a stop solution was added to the reaction solution, and the fluorescence was measured at 545 nm (excitation) and 585 nm (emission) using a FlexStation to measure enzyme activity. . The total volume of the reaction mixture was 40 μl and run on 384 black microwell plates. Detailed compositions of enzymes, substrates, and assay buffers used in the experiments are shown in Table 1 below.

Composition BACE-1 Enzyme Doll Recombinant BACE-1 (0.3 U / ml) BACE-1 Substrate Rhodamine-EVNLDAEFK-Quencher 250 nM BACE-1 fixative solution 2.5 M Sodium Acetate BACE-1 test buffer 50 mM sodium acetate (pH 4.5)

BACE-1 enzyme activity was measured by fluorescence analysis of the amount of substrate degradation at the end of the enzyme reaction, and the enzyme inhibition rate of the sample was calculated by comparing the enzyme activity of the control group without the sample and the enzyme activity of the test group without the sample. It was. First, measure the BACE-1 inhibition rate of the sample at the concentration of 10 ug / ml and 100 ug / ml, and dilute the sample step by step in the concentration gradient of 7-8 steps for the sample showing 50% or more inhibitory effect at each concentration The enzyme inhibition rate was determined, and the IC ₅₀ (50% enzyme inhibition concentration) value of each sample was determined by linear regression analysis on the dose-response curve. IC ₅₀ values of Peony seed ethanol extract are shown in Table 2 below.

ingredient IC ₅₀ (μg / ml) Peony Seed Ethanol Extract 18.0

As shown in Table 2,

It was confirmed that the IC ₅₀ value of the peony seed ethanol extract was 18.0 µg / ml.

< Experimental Example  2> Peony Seed Fraction BACE -1 inhibitory effect measurement

An IC ₅₀ value of the ethyl acetate fraction was obtained in the same manner as in Experimental Example 1, except that 10 μl of the ethyl acetate fraction was added.

ingredient IC ₅₀ (占 퐂 / ml) Ethyl acetate fraction 10.2

As shown in Table 3,

The ethyl acetate fraction of the peony seed was confirmed that the IC ₅₀ value was 10.2 μg / ml.

< Example  3> Peony Seed Ethyl Acetate From fractions Dichloromethane Methanol Fraction  Produce

128.6 g of the ethyl acetate fraction obtained in Example 2 was flowed at a flow rate of 3 ml / min using a dichloromethane / methanol mixed solution as a mobile phase, and the mixing ratio of dichloromethane / methanol was changed from 20: 1 to 1: 1. Concentration gradient eluted silica gel column chromatography was performed sequentially and divided into a total of six fractions (fractions A to F).

< Example  4> Peony Seeds Dichloromethane Methanol From fractions  Preparation of compounds

Of the six fractions obtained in Example 3, fractions B and C were subjected to silica gel column chromatography (dichloromethane / methanol 40: 1-1: 1 as a mobile phase, flow rate 3 ml / min) to give trans-resveratrol (B ₁ ), Bitisinol C (B ₂ ), bitisinol F (B ₃ ), cis-epsinon-viniferin (B ₄ ), 7a, 8a-cis-gypsin-vinifrine (B ₅ ). The novel compounds 7a, 8a-cis-cintron-viniprine and bitycinol F were identified using ¹ H-NMR, ¹³ C-NMR, HMQC, HMBC, DEPT, and NOE to formulas 1 and 2 Indicated.

Fractions D and E were also used to separate serupruticol A (D ₁ ), surfruticol B (D ₂ ) and gretin H (D ₃ ) using silica gel column chromatography and RP-18 column chromatography.

¹ H-NMR, ¹³ C-NMR analysis of the compounds isolated from the fractions B, C, D and E are shown in Table 4 below.

Compound structure data

[화학식 1]

[Formula 1] ¹ H-NMR (500 MHz, acetone-d ₆ ): δ 7.04 (2H, d, J = 8.6 Hz, H-2a, 6a), 6.63 (2H, d, J = 8.6 Hz, H-3a, 5a) , 5.87 (1H, d, J = 8.0 Hz, H7a), 4.70 (1H, d, J = 8.0 Hz, H-8a), 5.82 (1H, d, J = 2.0 Hz, H-10a), 5.98 (1H , t, J = 2.1 Hz, H-12a), 5.82 (1H, d, J = 2.0 Hz, H-14a), 7.24 (2H, d, J = 8.6 Hz, H-2b, 6b), 6.78 (2H , d, J = 8.6 Hz, H-3b, 5b), 6.78 (1H, d, J = 16.4 Hz, H-7b), 6.97 (1H, d, J = 16.4 Hz, H-8b), 6.39 (1H , d, J = 2.0 Hz, H-12b), 6.75 (1H, d, J = 2.0 Hz, H-13b).
¹³ C-NMR (125 MHz, acetone-d ₆ ): δ 162.5 (C-11b), 159.9 (C-11a, 13a), 159.6 (C-13b), 158.2 (C-4b), 158.2 (C-4a) , 147.5 (C-9a), 134.4 (C-9b), 133.9 (C-1a), 130.1 (C-7b), 129.9 (C-1b), 128.7 (C-2b, 6b), 128.0 (C-2a , 6a), 123.5 (C-8b), 119.9 (C-10b), 116.3 (C-3b, 5b), 116.2 (C-3a, 5a), 107.0 (C-10a, 14a), 104.4 (C-14b ), 102.1 (C-12a), 96.8 (C-12b), 93.9 (C-7a), 57.1 (C-8a).

(2) ¹ H-NMR (300 MHz, acetone-d ₆ ) δ: 7.36 (2H, d, J = 8.5 Hz, H-2b, 6b), 6.99 (1H, d, J = 16.0 Hz, H-8a), 6.94 (2H, d, J = 8.5 Hz, H-3b, 5b), 6.82 (2H, d, J = 8.5 Hz, H-2a, 6a), 6.71 (1H, d, J = 16.0 Hz, H-7a) , 6.68 (2H, d, J = 8.5 Hz, H-3a, 5a), 6.34 (1H, s, H-3), 6.11 (2H, d, J = 2.0 Hz, H-2c, 6c), 6.10 ( 1H, d, J = 2.0 Hz, H-4c), 4.17 (1H, br s, H-1), 3.86 (1H, d, J = 11.0 Hz, H-7), 3.15 (1H, t, J = 11.0 Hz, H-6), 2.95 (1H, dd, J = 11.0, 17.5 Hz, H-5a), 2.27 (1H, d, J = 17.5 Hz, H-5b), 1.23 (5H, t, J = 7.2 Hz, -OCH ₂ CH ₃ ).
¹³ C-NMR (125 MHz, acetone-d ₆ ) d: 201.6 (C-4), 173.3 (C = O), 159.3 (C-4a), 159.3 (C-3c), 159.3 (C-5c), 156.7 (C-4b), 148.7 (C-2), 147.4 (C-1c), 136.6 (C-1b), 135.2 (C-7a), 131.8 (C-3), 129.8 (C-2a), 129.8 (C-6a), 129.7 (C-8a), 129.4 (C-1a), 129.3 (C-2b), 129.3 (C-6b), 116.6 (C-3a), 116.6 (C-5a), 116.0 ( C-3b), 116.0 (C-5b), 107.4 (C-2c), 107.4 (C-6c), 101.9 (C-4c), 62.3 (-OCH ₂ ), 45.5 (C-7), 48.9 (C -5), 53.3 (C-6), 50.8 (C-1), 14.5 (-CH ₃ )

(3) ¹ H-NMR (300 MHz, acetone-d ₆ ): δ 7.33 (2H, d, J = 8.5, H-2 ', 6'), 6.94 (2H, d, J = 16.5, H-7 '), 6.79 (2H, d, J = 16.5, H-8 '), 6.75 (2H, d, J = 8.5, H-3', 5 '), 6.43 (2H, d, J = 2.5, H-2, 6 ), 6.14 (2H, doublet, J = 2.5, H-4).
¹³ C-NMR (75 MHz, acetone-d ₆ ): δ 159.7 (C-3, 5), 158.4 (C-10), 141.3 (C-1), 131.4 (C-7), 130.4 (C-13) , 129.4 (C-8), 128.8 (C-12), 127.0 (C-14), 116.5 (C-11), 115.8 (C-9), 108.2 (C-6), 105.8 (C-2), 102.6 (C-4).

[Chemical Formula 4] ¹ H-NMR (300 MHz, acetone-d ₆ ) δ: 7.12 (2H, d, J = 8.0 Hz, H-2, 6), 7.09 (2H, d, J = 8.0 Hz, H-2 ′, 6 '), 6.74 (2H, d, J = 8.0 Hz, H-3, 5), 6.64 (3H, br s, H-10, 12, 14), 6.35 (1H, d, J = 1.8 Hz, H- 14 '), 6.31 (1H, d, J = 4.0 Hz, H-7'), 6.07 (1H, d, J = 4.0 Hz, H-8 '), 6.04 (1H, d, J = 1.8 Hz, H -12 '), 5.33 (1H, d, J = 5.3 Hz, H-7), 4.09 (1H, J = 5.3 Hz, H-8).
¹³ C-NMR (75 MHz, acetone-d ₆ ) δ: 161.9 (C-11b), 158.9 (C-11a, 13a), 158.9 (C-13b), 157.5 (C-4b), 157.0 (C-4a ), 146.4 (C-9a), 136.4 (C-9b), 133.1 (C-1a), 130.6 (C-7b), 130.3 (C-2b), 130.3 (C-6b), 128.7 (C-1b) , 127.6 (C-2), 127.6 (C-6), 125.5 (C-8b), 119.4 (C-10b), 115.4 (C-3), 115.4 (C-5), 115.2 (C-3b), 115.2 (C-5b), 107.8 (C-14b), 106.2 (C-10), 106.2 (C-14), 101.2 (C-12), 96.0 (C-12b), 93.5 (C-7), 56.3 (C-8).

[Chemical Formula 5] ¹ H-NMR (300 MHz, acetone-d ₆ ) δ: 7.38 (2H, d, J = 8.5 Hz, H-2b, 6b), 6.93 (1H, d, J = 16.0 Hz, H-8a), 6.90 (2H, d, J = 8.5 Hz, H-2a, 6a), 6.83 (2H, d, J = 8.5 Hz, H-3b, 5b), 6.80 (1H, d, J = 16.0 Hz, H-7a) , 6.67 (2H, d, J = 8.5 Hz, H-3a, 5a), 6.64 (1H, s, H-3), 6.16 (2H, d, J = 2.0 Hz, H-2c, 6c), 6.13 ( 1H, m, H-4c), 3.21-3.00 (6H, m, H-1, 5, 6, 7).
¹³ C-NMR (125 MHz, acetone-d ₆ ) δ: 201.7 (C-4), 159.2 (C-4a, 3c), 156.6 (C-5c), 155.2 (C-4b, 2), 148.8 (C -1c), 136.9 (C-1b), 135.6 (C-7a), 131.7 (C-3), 129.8 (C-2a, 6a), 129.5 (C-2b, 6b, 1a), 129.3 (C-8a ), 116.5 (C-3a, 5a), 115.8 (C-3b, 5b), 107.2 (C-2c, 6c), 101.6 (C-4c), 52.6 (C-7), 50.5 (C-5), 46.5 (C-6), 34.7 (C-1).

[Formula 6] ¹ H-NMR (300 MHz, acetone-d ₆ ) δ: 7.28 (4H, dd, J = 1.8, 8.6 Hz, H-2a, 6a, 2c, 6c), 6.90 (2H, dd, J = 1.8, 8.7 Hz, H-2b, 6b), 6.86 (4H, dd, J = 1.8, 8.6 Hz, H-3a, 5a, 3c, 5c), 6.64 (2H, dd, J = 1.8, 8.7 Hz, H-3b, 5b), 6.63 (1H, d, J = 16.2 Hz, H-7b), 6.55 (1H, d, J = 16.2 Hz, H-8b), 6.49 (1H, s, H-12b), 6.26 (4H, d, J = 2.1 Hz, H-10a, 14a, H-10c, 14c), 6.22 (2H, d, J = 2.1 Hz, H-12a, 12c), 5.48 (2H, d, J = 5.1 Hz, H -7a, H-7c), 4.57 (2H, d, J = 5.1 Hz, H-8a, 8c).
¹³ C-NMR (75 MHz, acetone-d ₆ ) δ: 161.9 (C-11a, 11c, 13b), 159.1 (C-4a, 13a, 4c, 13c), 157.4 (C-4b, 11b), 146.8 (C -9a, 9c), 133.5 (C-9b), 133.3 (C-7b), 132.5 (C-1a, 1c), 129.7 (C-1b), 128.1 (C-2a, 6a, 2c, 6c), 127.5 (C-2b, 6b), 121.7 (C-8b), 119.5 (C-10b, 14b), 115.8 (C-3a, 5a, 3b, 5b, 3c, 5c), 106.7 (C-10a, 14a, C -10c, 14c), 101.7 (C-12a, 12c), 93.4 (C-8c), 93.4 (C-8a), 91.0 (C-12b), 57.4 (C-7a, 7c).

[Formula 7] ¹ H-NMR (300 MHz, CD ₃ OD) δ: 7.10 (2H, d, J = 8.8 Hz, H-2``, 6 ''), 6.95 (2H, d, J = 8.8 Hz, H-2 , 6), 6.68 (2H, d, J = 8.8 Hz, H-3 '', 5 '), 6.48 (2H, d, J = 8.8 Hz, 2', 6 '), 6. 37 (2H, d, J = 8.8 Hz, H-3, 5), 6.25 (1H, d, J = 2.2 Hz, H-12 ''), 6.19 (1H, d, J = 0.8 Hz, H-12 '), 6.12 (2H, d, J = 8.8 Hz, H-3 ', 5'), 6.06 (1H, t, J = 2.2 Hz, H-12), 5.98 (2H, d, J = 2.2 Hz, H-10, 14), 5.93 (1H, d, J = 1.8 Hz, H-14``), 5.68 (1H, d, J = 11.2 Hz, H-7``), 4.23 (1H, d, J = 3.2 Hz, H-7 '), 4.74 (1H, s, H-8), 4.35 (1H, d, J = 11.2 Hz, H-8``), 3.93 (1H, m, H-8'), 3.68 (1H , d, J = 8.0 Hz, H-7).
¹³ C-NMR (75 MHz, CD ₃ OD) δ: 160.2 (C-11 '), 159.3 (C-11, 13), 158.9 (C-4``), 156.7 (C-13''), 156.5 ( C-4), 155.1 (C-13 '), 154.9 (C-11``), 154.5 (C-4'), 148.4 (C-9), 144.7 (C-9 '), 141.8 (C-9 ''), 135.5 (C-1), 133.9 (C-1 '), 130.8 (C-1''), 130.7 (C-2', 6 '), 130.7 (C-2, 6), 130.5 ( C-2 '', 6 ''), 126.9 (C-10 ''), 123.0 (C-14 '), 117.3 (C-10'), 116.2 (C-3 '', 5 ''), 115.4 (C-3, 5), 114.2 (C-3 ', 5'), 106.8 (C-10, 14), 105.9 (C-14``), 101.9 (C-12 ''), 101.4 (C- 12), 96.2 (C-12 '), 91.5 (C-7``), 61.0 (C-7), 54.6 (C-8), 48.8 (C-8''), 48.6 (C-8') , 39.8 (C-7 ').

[Chemical Formula 8] ¹ H-NMR (300 MHz, CD ₃ OD) δ: 7.58 (2H, d, J = 8.8 Hz, H-2``, 6 ''), 6.92 (2H, brd, 2 ', 6'), 6.91 (2H, d, J = 8.8 Hz, H-3``, 5 ''), 6.50 (2H, d, J = 8.8 Hz, H-3 ', 5'), 6.29 (2H, d, J = 8.8 Hz, H-3, 5), 6.27 (2H, d, J = 8.8 Hz, H-2, 6), 6.24 (1H, s, H-10), 6.23 (1H, s, H-14), 6.22 (1H, s, H-12 '), 6.18 (1H, d, J = 2.2 Hz, H-12``), 6.15 (1H, t, J = 2.2 Hz, H-12), 5.95 (1H, d , J = 2.4 Hz, H-14``), 5.86 (1H, d, J = 11.2 Hz, H-7 ''), 5.09 (1H, d, J = 11.2 Hz, H-8 ''), 4.23 (1H, d, J = 11.2 Hz, H-7 '), 4.10 (1H, m, H-8'), 4.09 (1H, s, H-8), 3.81 (1H, d, J = 6.0 Hz, H-7).
¹³ C-NMR (75 MHz, CD ₃ OD) δ: 160.2 (C-11 ′), 159.4 (C-11, 13), 159.1 (C-4``), 158.4 (C-13``), 157.2 ( C-11 ''), 156.1 (C-4 '), 156.0 (C-4), 155.7 (C-13'), 147.5 (C-9 '), 147.5 (C-9), 142.4 (C-9 ''), 135.5 (C-1), 133.8 (C-1 '), 133.0 (C-2', 6 '), 130.9 (C-1''), 130.5 (C-2'',6'' ), 129.5 (C-2, 6), 123.6 (C-14 '), 122.9 (C-10''), 118.5 (C-10'), 116.5 (C-3``, 5 ''), 115.2 (C-3, 5), 114.7 (C-3 ', 5'), 107.4 (C-10, 14), 105.0 (C-12``), 103.7 (C-14 ''), 101.5 (C- 12), 96.3 (C-12 '), 91.1 (C-7''), 63.1 (C-7), 56.9 (C-8), 49.1 (C-8''), 47.8 (C-8') , 46.5 (C-7 ').

< Experimental Example  3> Peony Seed From fractions  Of the obtained compounds BACE -1 inhibition effect measurement

Trans-resveratrol obtained in Example 4, cis- epson-viniferin, 7a, 8a cissintron viniferin (7a, 8a-cis-ε-viniferin), Determination of BACE-1 inhibitory effects of vitisinol C, vitisinol F, gnetin H, suffruticosol A and suffruticosol B It was.

Except for using 10 μl of each compound instead of ethanol extract was carried out in the same manner as in Experimental Example 1 to obtain the IC ₅₀ value of each compound is shown in Table 5 below.

ingredient IC ₅₀ (μg / ml) 7a, 8a-cis- epsonology-viniferin (Formula 1) 11.90 Biticinol F (Formula 2) 2.21 Trans-Resveratrol (Formula 3) 1.29 Cis-Adrenalism-Viniferin (Formula 4) 4.01 Biticinol C (Formula 5) 1.43 Swingin H (Formula 6) 0.34 Surfactose A (Formula 7) 5.99 Surfacticosol B (Formula 8) 0.88

As shown in Table 5,

Compounds obtained from Peony seed fractions are trans-resveratrol, cis-epsinon-viniferin, 7a, 8a-cis-epsinon-viniferin, bitisinol C, bitisinol F, gretinine H, serruticosol A, supruti Corsol B was found to inhibit BACE-1 activity in a concentration-dependent manner with an IC ₅₀ value of 18.0 μg / ml or less. In particular, in the case of Swingin H, surfrutisol B showed a very good activity with an IC ₅₀ value of 1 or less, and the novel compounds 7a, 8a-cis- epson-viniprine and Vitisinol F also showed IC _50, respectively. Values of 1.29 and 1,43 showed good activity. Therefore, the compounds have excellent ability to inhibit BACE-1 activity, and thus may be usefully used as a preventive and therapeutic agent for degenerative brain diseases.

Formulation Example 1 Preparation of Pharmaceutical Formulation

1-1. Powder  Produce

Peony seed extract 500 mg

Lactose 100 mg

Talc 10 mg

The above ingredients are mixed and filled in an airtight cloth to prepare a powder.

1-2. Manufacture of tablets

Peony seed extract 500 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.

1-3. Manufacture of capsules

Peony seed extract 500 mg

Corn starch 100 mg

Lactose 100 mg

2 mg magnesium stearate

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

1-4. Injection preparation

Peony seed extract 500 mg

Sterile sterilized water for injection

pH adjuster

According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).

1-5. Liquid  Produce

Peony seed extract 100 mg

10 g of isomerized sugar

5 g of mannitol

Purified water

According to the conventional method of preparing a liquid solution, each component is added to the purified water to dissolve, the lemon flavor is added appropriately, the above components are mixed, purified water is added, the whole is adjusted to 100 ml by the addition of purified water, and then filled into a brown bottle. The liquid is prepared by sterilization.

Preparation Example 2 : Manufacture of health food

Peony Seed Extract 1000mg

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

0.13 mg of vitamin

0.15 mg of vitamin B ₂

0.5 mg of vitamin B ₆

Vitamin B ₁₂ 0.2 g

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folic acid 50 mg

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

The composition ratio of the above-mentioned vitamin and mineral mixture is mixed with a composition suitable for a health food in a preferred embodiment, but the compounding ratio may be arbitrarily modified. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Manufacturing example  3: manufacture of health drinks

Peony Seed Extract 1000mg

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered and sterilized in a sterilized 2 liter container, And used for manufacturing.

Although the composition ratio is a composition that is relatively suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Manufacturing example  4: Manufacture of Other Health Foods

4-1. Manufacturing of beverages

522 mg of honey

Chioctosanamide 5 mg

Nicotinamide 10 mg

Riboflavin Sodium Hydrochloride 3 mg

Pyridoxine hydrochloride 2 mg

Inositol 30 mg

Orthoic acid 50 mg

Peony Seed Extract 0.48 ~ 1.28 mg

200 ml of water

A beverage was prepared using the above-mentioned composition and content by a conventional method.

4-2. Of chewing gum  Produce

Gum base 20%

Sugar 76.36-76.76%

Peony Seed Extract 0.24 ~ 0.64%

1% fruit flavor

Water 2%

Chewing gum was prepared using conventional methods using the above composition and content.

4-3. Manufacture of candy

50-60% sugar

Starch syrup 39.26 ~ 49.66%

Peony Seed Extract 0.24 ~ 0.64%

Orange flavor 0.1%

The composition and the content of the candy were prepared using a conventional method.

4-4. Manufacture of flour food products

0.5 to 5 parts by weight of Peony seed extract was added to 100 parts by weight of wheat flour, and the mixture was used to prepare bread, cake, cookies, crackers, and noodles to prepare health promoting food.

4-5. dairy product( dairy products Manufacturing

5 to 10 parts by weight of peony seed extract was added to 100 parts by weight of milk, and the milk was used to prepare various dairy products such as butter and ice cream.

4-6. Solar  Produce

Brown rice, barley, glutinous rice, and yulmu were alphanated by a known method to distribute the dried ones, and then prepared into a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla were also steamed and dried in a known manner to prepare a powder having a particle size of 60 mesh using a grinder. The grains and seeds prepared above and the peony seed extract of the present invention were prepared by combining the following ratios.

Brown Rice 30%

15% rate

Barley 20%

Perilla 7%

Black Bean 7%

Black sesame 7%

Peony Seed Extract 3%

Ganoderma 0.5%

Foxglove 0.5%

Claims (24)

Peeonia lactiflora ) A pharmaceutical composition for preventing or treating degenerative brain disease, containing the extract of the seed as an active ingredient.
The pharmaceutical composition for preventing or treating degenerative brain disease according to claim 1, wherein the degenerative brain disease is Alzheimer's dementia (AD), Parkinson's disease, or advanced nuclear palsy.
[Claim 2] The pharmaceutical composition for preventing or treating degenerative brain disease according to claim 1, wherein the extract is extracted from peony seeds with water, C ₁ -C ₄ alcohol or a mixed solvent thereof.
The pharmaceutical composition for preventing or treating degenerative brain disease according to claim 3, wherein the C ₁ to C ₄ alcohol is methanol or ethanol.
A pharmaceutical composition for preventing or treating degenerative brain disease, which contains a fraction of peony seed as an active ingredient.
6. The pharmaceutical composition for preventing or treating degenerative brain disease according to claim 5, wherein the degenerative brain disease is Alzheimer's dementia (AD), Parkinson's disease, or advanced nuclear palsy.
7. The pharmaceutical composition for preventing or treating degenerative brain disease according to claim 6, wherein the fraction is obtained by sequentially dividing the extract of the peony seed of claim 1 with dichloromethane and ethyl acetate.
A pharmaceutical composition for preventing or treating degenerative brain disease, comprising as an active ingredient at least one compound selected from the group consisting of compounds of the following Chemical Formulas 1 to 8 isolated from the peony seed extract of claim 1.
[Formula 1]

(2)

(3)

[Chemical Formula 4]

[Chemical Formula 5]

[Formula 6]

[Formula 7]

[Chemical Formula 8]

Adding peony seed to water, C ₁ to C ₄ alcohol or a mixture thereof to obtain a peony seed extract (step 1);
Fractionating the extract obtained in step 1 with water, dichloromethane and ethyl acetate to obtain a fraction (step 2);
A method for preparing the compound of Formula 1 or Formula 8 according to claim 8, comprising performing the silica gel column chromatography on the fraction obtained in step 2 to separate and purify the compound (step 3).
The pharmaceutical composition for preventing or treating degenerative brain disease according to claim 9, wherein the C ₁ to C ₄ alcohol of step 1 is methanol or ethanol.
Health food for the prevention or improvement of degenerative brain disease, containing the extract of peony seed as an active ingredient.
12. The healthy food for preventing or improving degenerative brain disease according to claim 11, wherein the degenerative brain disease is Alzheimer's dementia (AD), Parkinson's disease, or advanced nuclear palsy.
The method for preventing or improving degenerative brain disease according to claim 11, wherein the extract is extracted from peony seeds with water, C ₁ to C ₄ alcohols, or a mixed solvent thereof.
According to claim 13, wherein the C ₁ ~ C ₄ alcohol is methanol or ethanol, characterized in that degenerative brain disease prevention or improvement health foods.
Health food for preventing or improving degenerative brain disease, containing fractions of peony seeds as active ingredients.
16. The healthy food for preventing or improving degenerative brain disease according to claim 15, wherein the degenerative brain disease is Alzheimer's dementia (AD), Parkinson's disease, or advanced nuclear palsy.
The health food for preventing or improving degenerative brain disease according to claim 15, wherein the fraction is obtained by sequentially dividing the extract of the peony seed of claim 11 with dichloromethane and ethyl acetate.
A health food for preventing or improving degenerative brain disease, which contains a compound isolated from at least one peony seed extract selected from the compounds of Formulas 1 to 8 as an active ingredient.
[Formula 1]

(2)

(3)

[Chemical Formula 4]

[Chemical Formula 5]

[Formula 6]

[Formula 7]

[Chemical Formula 8]

Adding peony seed to water, C ₁ to C ₄ alcohol or a mixture thereof to obtain a peony seed extract (step 1);
Fractionating the extract obtained in step 1 with water, dichloromethane and ethyl acetate to obtain a fraction (step 2);
The fraction obtained in step 2 is subjected to silica gel column chromatography to separate and purify the compound (step 3) characterized in that it is prepared by a method comprising a step for preventing or improving degenerative brain disease.
20. The method of claim 19, wherein the C ₁ ~ C ₄ alcohol of step 1 is methanol or ethanol, characterized in that degenerative brain disease prevention or improvement health foods.
20. The method for preventing or improving degenerative brain disease according to claim 19, wherein the degenerative brain disease is Alzheimer's dementia (AD), Parkinson's disease, or advanced nuclear palsy.
New compounds represented by the following general formula (1) or (2):
[Formula 1]

(2)

.
Adding peony seed to water, C ₁ to C ₄ alcohol or a mixture thereof to obtain a peony seed extract (step 1);
Fractionating the extract obtained in step 1 with water, dichloromethane and ethyl acetate to obtain a fraction (step 2);
A method for preparing the compound of Formula 1 or Formula 2 according to claim 23 comprising performing the silica gel column chromatography on the fraction obtained in step 2 to separate and purify the compound (step 3).
The pharmaceutical composition for preventing or treating degenerative brain disease according to claim 23, wherein the alcohol of C ₁ to C ₄ of step 1 is methanol or ethanol.

Images